We invest in life science companies whose key source of value creation is innovation and growth. Our investments come with an engaged and supportive approach to help a company, its board and its management realize their full potential.
The Principal Investment team targets investments in well-established life science companies with leading positions in attractive market segments and strong underlying growth drivers. We invest from our evergreen funds across the entire capital structure.
In addition to capital and engagement, an investment from Novo Holdings also provides access to our extensive network within the life science industry. We use our experience and expertise from our ownership of world-leading life science companies to actively support a board and management in realizing their strategic ambitions.
At the end of 2021, the Principal Investments portfolio comprised 16 companies, with a total value of EUR 9.5 billion.
Inogen develops, manufactures and markets innovative portable oxygen concentrators that deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Orexo is a specialty pharmaceutical company focused on the therapeutic areas of opioid addiction treatment and pain management.
Chr. Hansen is a global bioscience company that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries.
Xellia Pharmaceuticals is a manufacturing company focused on production of anti-infective treatments against serious and often life-threatening infections.
Sonion is a leading provider of technology solutions to the hearing aid industry.
Synlab is the largest laboratory service provider in Europe offering a full range of medical laboratory services for both clinical practice and hospital sectors, as well as areas such as within environmental monitoring, food safety and veterinary practice support.
Clario is a cloud platform solutions provider that supports the capture of efficacy and safety endpoints, harmonises data from any clinical source system, and delivers real-time insights, for optimal clinical trial performance.
Evotec is a leading drug discovery outsourcing company with a global client base. By combining cutting edge research technologies with well-established drug-discovery tools the company progresses product ideas from target to clinic. Evotec supports an increasing demand for high quality innovation with improved efficiency in the drug discovery process.
ConvaTec is a UK listed global medical products and technologies company with leading market positions in advanced wound care, ostomy care, continence and critical care and infusion devices.
Envirotainer is the market leader in the cold chain temperature controlled air logistics market. The company serves 600+ pharma companies with a fleet of 5,800 temperature controlled air freight containers.
WCG is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. The company enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protection. WCG is headquartered in Princeton, New Jersey. It serves over 3,000 institutional and academic medical centers and has over 2,000 employees around the world.
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.
Our team consists of highly skilled professionals with a diverse set of backgrounds including industry, consulting, banking and private equity. We use our broad life science expertise to target long-term investment opportunities.
Value of investments at the end of 2021.
Portfolio companies as of Dec 2021
The Principal Investments team is based at our headquarters in Copenhagen, Denmark.
Novo Holdings A/S
Tuborg Havnevej 19
2900 Hellerup
Denmark
+45 3527 6500
CVR# 24257630
Principal Investments*
200 Clarendon Street, Floor 45
Boston, MA 02116
USA
*) Principal Investments is a team of business professionals employed by Novo Holdings Equity US Inc., which is a separate legal entity that provides certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.